TABLE OF CONTENTS
1 INTRODUCTION 86
1.1 OBJECTIVES OF THE STUDY 86
1.2 MARKET DEFINITION 86
1.3 OVERVIEW OF THE GLOBAL DYSPEPSIA DRUG MARKET 86
1.4 CURRENCY AND PRICING 88
1.5 LIMITATIONS 88
1.6 MARKETS COVERED 88
2 MARKET SEGMENTATION 92
2.1 MARKETS COVERED 92
2.2 GEOGRAPHICAL SCOPE 93
2.3 YEARS CONSIDERED FOR THE STUDY 94
2.4 DBMR TRIPOD DATA VALIDATION MODEL 95
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 98
2.6 MULTIVARIATE MODELLING 99
2.7 TYPE LIFELINE CURVE 99
2.8 DBMR MARKET POSITION GRID 100
2.9 VENDOR SHARE ANALYSIS 102
2.10 MARKET END-USER COVERAGE GRID 103
2.11 SECONDARY SOURCES 104
2.12 ASSUMPTIONS 104
3 EXECUTIVE SUMMARY 105
4 PREMIUM INSIGHT 109
4.1 PESTEL ANALYSIS 111
4.2 PORTERS FIVE FORCES 112
5 EPIDEMIOLOGY 113
6 PROBLEMS IN THE MANAGEMENT OF DYSPEPSIA 114
7 INDUSTRY INSIGHTS: 115
8 GLOBAL DYSPEPSIA DRUG MARKET, REGULATION 116
9 MARKET OVERVIEW 119
9.1 DRIVERS 121
9.1.1 INCREASING PREVALENCE OF DYSPEPSIA 121
9.1.2 RISE IN THE ADOPTION OF UNHEALTHY LIFESTYLE 121
9.1.3 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS 122
9.2 RESTRAINTS 123
9.2.1 POSSIBLE SIDE EFFECTS OF THE DRUGS USED FOR DYSPEPSIA 123
9.2.2 INCREASING PREFERENCE FOR NATURAL AND HERBAL REMEDIES 124
9.3 OPPORTUNITIES 124
9.3.1 GROWING AGING POPULATION 124
9.3.2 RISE IN THE DRUG APPROVAL 125
9.4 CHALLENGES 126
9.4.1 LACK OF AWARENESS ABOUT DYSPEPSIA AMONG THE POPULATION 126
9.4.2 STRINGENT REGULATIONS 126
10 GLOBAL DYSPEPSIA DRUG MARKET, BY TYPE 127
10.1 OVERVIEW 128
10.2 NON-ULCER DYSPEPSIA 131
10.3 ORGANIC DYSPEPSIA 131
10.4 DRUG INDUCED DYSPEPSIA 132
10.5 OTHERS 133
11 GLOBAL DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE 134
11.1 OVERVIEW 135
11.2 MEDICATION 138
11.2.1 DRUGS 139
11.2.1.1 ANTACIDS 139
11.2.1.1.1 PROTON PUMP INHIBITORS (PPIS) 139
11.2.1.1.1.1 OMEPRAZOLE 140
11.2.1.1.1.2 LANSOPRAZOLE 140
11.2.1.1.1.3 ESOMEPRAZOLE 140
11.2.1.1.1.4 OTHERS 140
11.2.1.1.2 H2 BLOCKERS 140
11.2.1.1.2.1 CIMETIDINE 141
11.2.1.1.2.2 FAMOTIDINE 141
11.2.1.1.2.3 NIZATIDINE 141
11.2.1.1.2.4 RANITIDINE 141
11.2.1.1.2.5 OTHERS 141
11.2.1.2 GASTRIC PROKINETIC GENDERNTS 141
11.2.1.2.1 MOSAPRIDE CITRATE 142
11.2.1.2.2 METOCLOPRAMIDE 142
11.2.1.2.3 CISAPRIDE 142
11.2.1.2.4 ITOPRIDE HYDROCHLORIDE 142
11.2.1.2.5 DOMPERIDONE 142
11.2.1.2.6 OTHERS 143
11.2.1.3 ANTIBIOTICS 143
11.2.1.3.1 REFAXIMIN 143
11.2.1.3.2 AMOXICILLIN 143
11.2.1.3.3 CLARITHROMYCIN 143
11.2.1.3.4 METRONIDAZOLE 144
11.2.1.3.5 LEVOFLOXACIN 144
11.2.1.3.6 TETRACYCLINE 144
11.2.1.3.7 OTHERS 144
11.2.1.4 OTHERS 144
11.2.2 NON- DRUGS 144
11.2.2.1 PROBIOTICS 144
11.2.2.1.1 LACTOBACILLUS 145
11.2.2.1.2 BIFIDOBACTERIUM 145
11.2.2.1.3 BACILLUS 145
11.2.2.1.4 STREPTOCOCCUS 145
11.2.2.1.5 OTHERS 145
11.2.2.2 PREBIOTICS 145
11.3 SURGERY 146
12 GLOBAL DYSPEPSIA DRUG MARKET, BY DRUG TYPE 147
12.1 OVERVIEW 148
12.2 GENERIC 151
12.3 BRANDED 152
13 GLOBAL DYSPEPSIA DRUG MARKET, BY PRESCRIPTION 153
13.1 OVERVIEW 154
13.2 WITHOUT PRESCRIPTION DRUGS 157
13.3 PRESCRIPTION DRUGS 158
14 GLOBAL DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION 159
14.1 OVERVIEW 160
14.2 ORAL 163
14.2.1 TABLETS 163
14.2.2 CAPSULES 164
14.3 INJECTABLE 164
15 GLOBAL DYSPEPSIA DRUG MARKET, BY GENDER 165
15.1 OVERVIEW 166
15.2 FEMALE 169
15.2.1 30-50 YEARS 170
15.2.2 MORE THAN 50 YEARS 170
15.2.3 AGE LESS THAN 30 170
15.3 MALE 170
15.3.1 30-50 YEARS 171
15.3.2 MORE THAN 50 YEARS 171
15.3.3 AGE LESS THAN 30 171
16 GLOBAL DYSPEPSIA DRUG MARKET, BY END USER 172
16.1 OVERVIEW 173
16.2 HOSPITALS 176
16.2.1 TYPE 176
16.2.1.1 PUBLIC 177
16.2.1.2 PRIVATE 177
16.2.2 TIER 177
16.2.2.1 TIER 3 177
16.2.2.2 TIER 2 177
16.2.2.3 TEIR 1 177
16.3 CLINICS 177
16.4 HOMECARE SETTINGS 178
16.5 SPECIALTY CLINICS 179
16.6 AMBULATORY CENTERS 180
16.7 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 180
16.8 OTHERS 181
17 GLOBAL DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL 182
17.1 OVERVIEW 183
17.2 RETAIL SALES 186
17.2.1 REATIL PHARMACY 187
17.2.2 HOSPITAL PHARMACY 187
17.2.3 ONLINE PHARMACY 187
17.3 DIRECT TENDER 187
18 GLOBAL DYSPEPSIA DRUG MARKET, BY REGION 188
18.1 OVERVIEW 189
18.2 NORTH AMERICA 195
18.2.1 U.S. 208
18.2.2 CANADA 216
18.2.3 MEXICO 225
18.3 EUROPE 234
18.3.1 GERMANY 248
18.3.2 U.K. 258
18.3.3 ITALY 268
18.3.4 FRANCE 278
18.3.5 SPAIN 288
18.3.6 RUSSIA 298
18.3.7 SWITZERLAND 308
18.3.8 TURKEY 318
18.3.9 BELGIUM 328
18.3.10 NETHERLANDS 338
18.3.11 DENMARK 348
18.3.12 SWEDEN 358
18.3.13 POLAND 368
18.3.14 NORWAY 378
18.3.15 FINLAND 388
18.3.16 REST OF EUROPE 398
18.4 ASIA-PACIFIC 399
18.4.1 JAPAN 414
18.4.2 CHINA 425
18.4.3 SOUTH KOREA 436
18.4.4 INDIA 447
18.4.5 AUSTRALIA 457
18.4.6 NEW ZEALAND 468
18.4.7 SINGAPORE 480
18.4.8 THAILAND 491
18.4.9 INDONESIA 502
18.4.10 MALAYSIA 513
18.4.11 PHILIPPINES 524
18.4.12 VIETNAM 535
18.4.13 TAIWAN 546
18.4.14 REST OF ASIA-PACIFIC 557
18.5 SOUTH AMERICA 558
18.5.1 BRAZIL 571
18.5.2 ARGENTINA 580
18.5.3 REST OF SOUTH AMERICA 589
18.6 MIDDLE EAST AND AFRICA 590
18.6.1 SOUTH AFRICA 603
18.6.2 EGYPT 612
18.6.3 BAHRAIN 620
18.6.4 U.A.E 629
18.6.5 SAUDI ARABIA 637
18.6.6 KUWAIT 646
18.6.7 OMAN 655
18.6.8 QATAR 663
18.6.9 REST OF MIDDLE EAST AND AFRICA 671
19 GLOBAL DYSPEPSIA DRUG MARKET, COMPANY LANDSCAPE 672
19.1 COMPANY SHARE ANALYSIS: GLOBAL 672
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 673
19.3 COMPANY SHARE ANALYSIS: EUROPE 674
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 675
20 SWOT ANALYSIS 676
21 GLOBAL DYSPEPSIA DRUG MARKET, COMPANY PROFILINGS 677
21.1 SANOFI 677
21.1.1 COMPANY SNAPSHOT 677
21.1.2 REVENUE ANALYSIS 677
21.1.3 COMPANY SHARE ANALYSIS 678
21.1.4 PRODUCT PORTFOLIO 678
21.1.5 RECENT DEVELOPMENT 678
21.2 LUPIN 679
21.2.1 COMPANY SNAPSHOT 679
21.2.2 REVENUE ANALYSIS 679
21.2.3 COMPANY SHARE ANALYSIS 680
21.2.4 PRODUCT PORTFOLIO 680
21.2.5 RECENT DEVELOPMENTS 680
21.3 MANKIND PHARMA 681
21.3.1 COMPANY SNAPSHOT 681
21.3.2 REVENUE ANALYSIS 681
21.3.3 COMPANY SHARE ANALYSIS 682
21.3.4 PRODUCT PORTFOLIO 682
21.3.5 RECENT DEVELOPMENT 682
21.4 ASTRAZENECA 683
21.4.1 COMPANY SNAPSHOT 683
21.4.2 REVENUE ANALYSIS 683
21.4.3 COMPANY SHARE ANALYSIS 684
21.4.4 PRODUCT PORTFOLIO 684
21.4.5 RECENT DEVELOPMENT 684
21.5 BAYER AG 685
21.5.1 COMPANY SNAPSHOT 685
21.5.2 REVENUE ANALYSIS 685
21.5.3 COMPANY SHARE ANALYSIS 686
21.5.4 PRODUCT PORTFOLIO 686
21.5.5 RECENT DEVELOPMENT 686
21.6 ABBOTT 687
21.6.1 COMPANY SNAPSHOT 687
21.6.2 REVENUE ANALYSIS 687
21.6.3 PRODUCT PORTFOLIO 688
21.6.4 RECENT DEVELOPMENT 688
21.7 ANI PHARMACEUTICALS, INC. 689
21.7.1 COMPANY SNAPSHOT 689
21.7.2 REVENUE ANALYSIS 689
21.7.3 PRODUCT PORTFOLIO 690
21.7.4 RECENT DEVELOPMENT 690
21.8 AOSAIKANG PHARMACEUTICAL CO., LTD. 691
21.8.1 COMPANY SNAPSHOT 691
21.8.2 REVENUE ANALYSIS 691
21.8.3 PRODUCT PORTFOLIO 692
21.8.4 RECENT DEVELOPMENT 692
21.9 ASTERISK LABORATORIES (I) PVT. LTD 693
21.9.1 COMPANY SNAPSHOT 693
21.9.2 PRODUCT PORTFOLIO 693
21.9.3 RECENT DEVELOPMENT 693
21.10 CADILA PHARMACEUTICALS 694
21.10.1 COMPANY SNAPSHOT 694
21.10.2 REVENUE ANALYSIS 694
21.10.3 COMPANY SHARE ANALYSIS 695
21.10.4 PRODUCT PORTFOLIO 695
21.10.5 RECENT DEVELOPMENT 695

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.